• Dual IDO1, PD-L1 inhibition safe for advanced solid tumors

    One year ago - By Healio

    Aung Naing
    The addition of the highly selective IDO1 inhibitor epacadostat to the PD-L1 inhibitor durvalumab appeared safe for patients with advanced solid tumors, according to results of the ECHO-203 trial presented at American Association for Cancer Research Annual Meeting.
    “IDO1 is an intracellular enzyme that catalyzes the first and rate-limiting step of tryptophan. This degradation is important in the kynurenine pathway,” Aung Naing, MD, FACP, associate professor in the department of investigational cancer therapeutics at The University of Texas MD Anderson Cancer Center, said
    Read more ...